The current valuation score of ALX Oncology Holdings Inc is 8.74, ranking 63 out of 385 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.30, which is -87.28% below the recent high of -0.17 and -263.40% above the recent low of -4.73.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.